Genflow Biosciences Reports Half-Year Results for 2026

Genflow Biosciences PLC has announced its half-year financial results for the period ending June 30, 2026. As of this date, the company achieved a major milestone with the successful completion of SLAB, a clinical trial focused on canine healthspan and sarcopenia, which confirmed the safety of its GF-1004 treatment in aged Beagle dogs. This accomplishment signifies a significant advancement in the application of the SIRT6 centenarian gene platform.

In the animal health sector, the noteworthy completion of the SLAB trial validates Genflow's SIRT6 cent platform, reinforcing the company’s position in veterinary medicine. The trial yielded valuable healthspan data and confirmed GF-1004’s tolerability, with full results expected to be presented at the Animal Longevity Summit in Toronto on October 2, 2026.

Genflow's human health pipeline covers multiple programs, including metabolic dysfunction-associated steatosis (MASH), sarcopenia, and initiatives in ophthalmology. The company has transitioned to using mRNA-lipid nanoparticle (mRNA-LNP) delivery methods, particularly for a new glaucoma program developed in partnership with Iris Pharma and Acuitas, potentially targeting a market projected to grow to nearly USD 14 billion by the early 2030s.

Financially, as of June 30, 2026, Genflow reported cash reserves of £632,553, up from £111,792 at the end of 2025. The report indicated administrative expenses of £454,311 for the first half of 2026, a reduction from £982,725 in the same period of the previous year. The company also recorded a loss of £420,233 for the half-year.

Looking ahead, Genflow is focused on further advancing its research initiatives across both human and animal health sectors, while seeking additional funding to support its development programs. Its strategic integration of human and animal health research aims to expand the SIRT6 platform and its therapeutic applications in age-related diseases.

For further information, contact Dr. Eric Leire, CEO of Genflow Biosciences, or Eric Laub from ON365 Partners Inc. This announcement is classified as inside information under Market Abuse Regulation (EU) No. 596/2014.